Introduction: Urinary tract infections (UTIs) are among the most common bacterial infections encountered in clinical practice. The emergence of fluoroquinolone resistance poses a significant challenge to their management, given their frequent use as first-line therapy. Objectives: This retrospective study evaluates the prevalence, risk factors, and antimicrobial susceptibility patterns of fluoroquinolone-resistant uropathogens isolated from patients at G.B. Pant Hospital, Delhi, over one year (January 2023 to December 2023). Methods: Urine samples collected from inpatients and outpatients with clinically suspected UTIs were processed by standard microbiological techniques. Antimicrobial susceptibility testing was performed following CLSI guidelines 2023. Results: Among 1,243 uropathogens with significant growth, 872 isolates (70.2, 95 CI: 67.6-72.7) were resistant to fluoroquinolones. The most common pathogen showing fluoroquinolone-resistance was Escherichia coli (76.1, 95 CI: 73.1-78.9). Prior antibiotic use (adjusted OR: 1.70, 95 CI: 1.24-2.33, p0.001), diabetes mellitus (adjusted OR: 1.38, 95 CI: 1.03-1.86, p0.032) and recurrent UTIs (adjusted OR: 1.95, 95 CI: 1.43-2.66, pConclusion: Alternative agents including fosfomycin (91.4 susceptibility), nitrofurantoin (85.6), and carbapenems (92.3) demonstrated good activity against fluoroquinolone-resistant isolates. Our findings highlight the growing resistance trends, providing insights into epidemiological and microbiological data to inform empiric therapy and antimicrobial stewardship policies.
Goenka et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: